PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1-positive NSCLC.
CLINICAL TRIAL REGISTRATION NCT07144280 (https://clinicaltrials.gov/study/NCT07144280).
We have 3 of 33 papers
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
CLINICAL TRIAL REGISTRATION NCT07144280 (https://clinicaltrials.gov/study/NCT07144280).
The type of immune checkpoint inhibitor used in combination with chemotherapy did not significantly influence treatment outcomes, however, the presence of liver metastases emerged as a major adverse prognostic factor associated with shorter OS and PFS in patients with ES-SCLC treated with chemoimmunotherapy.
In this multinational real-world cohort, outcomes with first-line chemo-immunotherapy were consistent with CASPIAN trial and the addition of cRT or sRT appeared feasible, safe, and associated with clinically meaningful survival improvements.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.